NCT00007956View on ClinicalTrials.gov

Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma

PHASE1CompletedINTERVENTIONAL
Timeline

Start Date

November 30, 2000

Conditions
Lymphoma
Interventions
BIOLOGICAL

monoclonal antibody mono-dgA-RFB4

Trial Locations (2)

20892

Center for Cancer Research, Bethesda

20892-1182

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00007956 - Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma | Biotech Hunter | Biotech Hunter